March Biosciences receives FDA RMAT designation for CD5-targeted CAR-T cell therapy, while Oncotelic Therapeutics and Sapu Bioscience define sub-15 nm nanoparticles as a new frontier in drug delivery, potentially revolutionizing treatment approaches for T-cell lymphoma and other cancers.
